Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount

Pliant Therapeutics

11/08/2026 21:19

Overview
US biopharmaceutical firm's Q2 net loss narrowed from prior year
Q2 operating expenses fell sharply after discontinuing bexotegrast program and reducing headcount
Company reports strong enrollment in FORTIFY Phase 1b oncology trial

Outlook
Company expects interim data from FORTIFY trial in 2027
Pliant plans to provide additional detail on integrin-targeted delivery platform in H2 2026
Company expects cash, cash equivalents and short-term investments to fund operations into H2 2028

Result Drivers
FORTIFY ENROLLMENT - Strong enrollment in FORTIFY Phase 1b trial for PLN-101095 progressing ahead of schedule
BIOMARKER DATA - Updated Phase 1 monotherapy biomarker data showed coordinated T-cell reactivation cascade in responders
LOWER OPERATING EXPENSES - Operating expenses declined due to completion of BEACON-IPF close-out activities and reduced headcount

Company press release: ID:nGNX3GXKjX

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$22.37 mln
 
Q2 Operating Expenses
 
$23.86 mln
 
Q2 Operating Income
 
-$23.86 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Pliant Therapeutics, Inc. is $2.50, about 140.4% above its August 10 closing price of $1.04

Reuters Recommended Reads
Aug 11 - Kalaris Therapeutics Q2 net loss narrows on lower administrative costs 
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 10 - Tenax heart drug fails to improve walking results in study, shares plunge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)